{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"EXOZ","limit":50},"count":28,"signals":[{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":23,"context":"eedings more effectively than we can because they have greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Intellectual property litigation and other proceedings may, regardless of their merit, also absorb significant management time and employee resources. **","filed_date":"2026-03-30","accession":"0001493152-26-013563","full_text":"https://origin.rootz.global/static/filing/0001493152-26-013563.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":25,"context":"annual meeting of shareholders and until their successors are duly elected and qualified; | | | 2. | To consider and vote on a non-binding advisory resolution to approve the compensation paid to our named executive officers for our 2025 fiscal year (commonly known as say-on-pay); | | | 3. | To consider and vote on a non-binding advisory determination of the frequency of future advisory votes on the compensation paid to","filed_date":"2025-06-20","accession":"0001140361-25-023217","full_text":"https://origin.rootz.global/static/filing/0001140361-25-023217.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":23,"context":"s more effectively than we can because of their having greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Intellectual property litigation and other proceedings may, regardless of their merit, also absorb significant management time and employee resources. **","filed_date":"2025-03-31","accession":"0001641172-25-001744","full_text":"https://origin.rootz.global/static/filing/0001641172-25-001744.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":5,"context":"s more effectively than we can because of their having greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Intellectual property litigation and other proceedings may, regardless of their merit, also absorb significant management time and employee resources. **","filed_date":"2024-10-21","accession":"0001493152-24-041726","full_text":"https://origin.rootz.global/static/filing/0001493152-24-041726.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"re, and (iii) the Company agreed to pay Michael Heltzen a one-time bonus equal to $250,000.00 in the aggregate. The option grant provides that it vest over a four year period, in equal quarterly installments at the end of each calendar quarter, and the Options will commence vesting on July 1, 2025, and expires June 29, 2032.  2020 Equity Incentive Plan  The Company adopted an equity incentive award p","filed_date":"2025-06-20","accession":"0001140361-25-023217","full_text":"https://origin.rootz.global/static/filing/0001140361-25-023217.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":87,"match_count":4,"context":"s more effectively than we can because of their having greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Intellectual property litigation and other proceedings may, regardless of their merit, also absorb significant management time and employee resources. **","filed_date":"2024-02-09","accession":"0001493152-24-005725","full_text":"https://origin.rootz.global/static/filing/0001493152-24-005725.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":85,"match_count":10,"context":"ring when extraordinary opportunity presents itself like our isobutanol project. | | **Key terms of the license agreement with the Regents of the University of California** **** On April 26, 2019, we entered into a licensing agreement with The Regents of The University of California, through the University of California, Los Angles (UCLA). This agreement pertains to certain patent rights, notably encompassing: (i) pathway designs","filed_date":"2025-03-31","accession":"0001641172-25-001744","full_text":"https://origin.rootz.global/static/filing/0001641172-25-001744.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":77,"match_count":9,"context":"nufacturing when extraordinary opportunity presents itself like our isobutanol project. | | *Key terms of the license agreement with the Regents of the University of California* On April 26, 2019, we entered into a licensing agreement with The Regents of The University of California, through the University of California, Los Angles (UCLA). This agreement pertains to certain patent rights, notably encompassing: (i) pathway designs","filed_date":"2026-03-30","accession":"0001493152-26-013563","full_text":"https://origin.rootz.global/static/filing/0001493152-26-013563.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":71,"match_count":7,"context":"ynthesis of Coenzyme A and Acetyl-CoA for Cell-Free Biocatalysis | | | 42 | | | | | **Key terms of the license agreement with the Regents of the University of California** ** ** On April 26, 2019, we entered into a licensing agreement with The Regents of The University of California, through the University of California, Los Angles (UCLA). This agreement pertains to certain patent rights, notably encompassing: (i) pathway designs","filed_date":"2024-10-21","accession":"0001493152-24-041726","full_text":"https://origin.rootz.global/static/filing/0001493152-24-041726.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":66,"match_count":7,"context":"cal-oriented systems and biomanufacturing. | | |  | | Commodity chemical and fuel-focused systems and biomanufacturing | | **Key terms of the license agreement with UCLA** ** ** On April 26, 2019, we entered into a licensing agreement with The Regents of The University of California. This agreement pertains to certain patent rights, notably encompassing: (i) pathway designs for the balance of co-factors in a cell-free system, and","filed_date":"2024-02-09","accession":"0001493152-24-005725","full_text":"https://origin.rootz.global/static/filing/0001493152-24-005725.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":48,"match_count":6,"context":"of Security Holders** The 2025 Annual Meeting of Stockholders (the Annual Meeting) of eXoZymes Inc. (the Company) was held on July 25, 2025. At the Annual Meeting, the Companys shareholders: |  |  |  Elected six nominees to serve as directors until the 2026 annual meeting of shareholders and until their successors are duly elected and qualified; | | |  |  |  | | |  |  |  Considered and voted on a non-binding advisory resolution to approv","filed_date":"2025-07-28","accession":"0001641172-25-021084","full_text":"https://origin.rootz.global/static/filing/0001641172-25-021084.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":34,"match_count":3,"context":"ART II OTHER INFORMATION** **Item 1. Legal Proceedings** We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened litigation that would have a material adverse effect on our business, operating results, cash flows, or financial condition should such litigation be resolved unfavorably. We believe that from time to time we will have commercial disputes arising in th","filed_date":"2025-11-13","accession":"0001493152-25-022289","full_text":"https://origin.rootz.global/static/filing/0001493152-25-022289.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":34,"match_count":3,"context":"ART II OTHER INFORMATION** **Item 1. Legal Proceedings** We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened litigation that would have a material adverse effect on our business, operating results, cash flows, or financial condition should such litigation be resolved unfavorably. We believe that from time to time we will have commercial disputes arising in th","filed_date":"2025-08-12","accession":"0001641172-25-023184","full_text":"https://origin.rootz.global/static/filing/0001641172-25-023184.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":34,"match_count":3,"context":"ART II OTHER INFORMATION** **Item 1. Legal Proceedings** We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened litigation that would have a material adverse effect on our business, operating results, cash flows, or financial condition should such litigation be resolved unfavorably. We believe that from time to time we will have commercial disputes arising in th","filed_date":"2025-05-12","accession":"0001641172-25-009636","full_text":"https://origin.rootz.global/static/filing/0001641172-25-009636.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":34,"match_count":3,"context":"ART II OTHER INFORMATION** **Item 1. Legal Proceedings** We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened litigation that would have a material adverse effect on our business, operating results, cash flows, or financial condition should such litigation be resolved unfavorably. We believe that from time to time we will have commercial disputes arising in th","filed_date":"2026-08-13","accession":"0001493152-26-037725","full_text":"https://origin.rootz.global/static/filing/0001493152-26-037725.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"platform_shift","strength":24,"match_count":3,"context":"additives, and novel compounds. We believe that SimplePath not only can maximize the value of these resources but also will contribute to the development of novel chemical compounds that should open new markets and business opportunities. Our SimplePath platform consists of a series of modular cascading enzyme based biomanufacturing systems that leverage natural processes to perform complex chemical conver","filed_date":"2024-02-09","accession":"0001493152-24-005725","full_text":"https://origin.rootz.global/static/filing/0001493152-24-005725.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":18,"match_count":1,"context":"ART II OTHER INFORMATION** **Item 1. Legal Proceedings** We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened litigation that would have a material adverse effect on our business, operating results, cash flows, or financial condition should such litigation be resolved unfavorably. We believe that from time to time we will have commercial disputes arising in th","filed_date":"2024-11-12","accession":"0001493152-24-044813","full_text":"https://origin.rootz.global/static/filing/0001493152-24-044813.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"backlog_growth","strength":16,"match_count":2,"context":"proven manufacturing processes at commercial scale, for a particular chemical or set of chemicals, we believe that we will be able to enter the market to offer processes that will be able to meet the growing demand for sustainable, high-quality, chemical products. *Research and Development Grants* We have received US government grants, particularly from the Department of Energy (DOE) for work related to isobuta","filed_date":"2024-10-21","accession":"0001493152-24-041726","full_text":"https://origin.rootz.global/static/filing/0001493152-24-041726.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"platform_shift","strength":16,"match_count":2,"context":"ls, food additives, for example. We believe that SimplePath not only can maximize the value of these chemicals but also will contribute to the development of novel chemical compounds that should open new markets and business opportunities. Invizyne was established in 2019, and is a pre-revenue, development stage company. Our primary operational activities to date have been development of the SimplePath plat","filed_date":"2024-10-21","accession":"0001493152-24-041726","full_text":"https://origin.rootz.global/static/filing/0001493152-24-041726.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"backlog_growth","strength":16,"match_count":2,"context":"tion capabilities. Once there is indication of proven manufacturing processes at commercial scale, we believe that we will be able to enter the market to offer processes that will be able to meet the growing demand for sustainable, high-quality, chemical products. We are committed to innovation. We have received substantial US government grants, particularly from the Department of Energy (DOE) for work related","filed_date":"2024-02-09","accession":"0001493152-24-005725","full_text":"https://origin.rootz.global/static/filing/0001493152-24-005725.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":13,"match_count":1,"context":"on Senior Securities None. **Item 4. Mine Safety Disclosures** Not applicable. **Item 5. Other Information** Tyler Korman previously serving as the Vice President of Research and Development has been promoted to Chief Science Officer. The promotion was approved by the Board of Directors on November 10, 2025. Also on November 10, 2025, in connection with his promotion, the Compensation Committee and the Board increased Mr.Kormans","filed_date":"2025-11-13","accession":"0001493152-25-022289","full_text":"https://origin.rootz.global/static/filing/0001493152-25-022289.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"aining amount restricted stock units. The option portion and the restricted stock portion will each vest 25% on the first anniversary of his employment and the balance will vest in equal monthly installments over the following 36 months. Mr. Perriman will be entitled to participate in the employee benefit plans and programs as are made available to similarly situated employees of the Company. The emp","filed_date":"2026-03-30","accession":"0001493152-26-013563","full_text":"https://origin.rootz.global/static/filing/0001493152-26-013563.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"platform_shift","strength":8,"match_count":1,"context":"ied projects in accordance with corporate business plans, including strategic mergers, acquisitions or divestitures; (12)total stockholder return; (13)debt reduction; (14)market share; (15)entry into new markets, either geographically or by business unit; (16)net new members of the Company; (17)member retention and satisfaction; (18)strategic plan development and implementation, including turnaround plans;","filed_date":"2025-06-20","accession":"0001140361-25-023217","full_text":"https://origin.rootz.global/static/filing/0001140361-25-023217.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":8,"match_count":1,"context":"ing guidelines and policies with respect to risk assessment and risk management. Our audit committee monitors compliance with legal and regulatory requirements and is responsible for the oversight of cybersecurity risks  Family Relationships  There are no family relationships between our Board and any of our executive officers.  Director Independence  Generally, under the listing requirements and rules","filed_date":"2025-06-20","accession":"0001140361-25-023217","full_text":"https://origin.rootz.global/static/filing/0001140361-25-023217.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"f Common Stock, and (iii) the Company agreed to pay Michael Heltzen a one-time bonus equal to $250,000.00 in the aggregate. The Options would vest over a four (4) year period, in equal quarterly installments at the end of each quarter of the calendar year, and the Options would commence vesting on July 1, 2025. The option expires June 29, 2032. |  Item 9.01. |  Financial Statements and Exhibits. | |","filed_date":"2025-06-20","accession":"0001641172-25-015782","full_text":"https://origin.rootz.global/static/filing/0001641172-25-015782.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"platform_shift","strength":8,"match_count":1,"context":"o make. The SimplePath platform not only can maximize the value of these resources but also can contribute to the development of novel and renewable chemical compounds that hold the potential to open new markets and business opportunities. For more information, please visit www.invizyne.com **Forward-Looking Statements** * * *This press release contains forward-looking statements. These forward-looking stat","filed_date":"2024-11-18","accession":"0001493152-24-046545","full_text":"https://origin.rootz.global/static/filing/0001493152-24-046545.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"capex_increase","strength":8,"match_count":1,"context":"he offering amount. Any additional amounts received from the exercise of the over-allotment option will be added to working capital and other general purposes. |  Expansion of production capabilities increase in capital expenditures | |  $ | 3,500,000 |  | | |  Increase in staff | |  $ | 4,000,000 |  | | |  Expanding Business Development, Sales, and marketing | |  $ | 500,000 |  | | |  Expanding the R&D and technology platform |","filed_date":"2024-10-21","accession":"0001493152-24-041726","full_text":"https://origin.rootz.global/static/filing/0001493152-24-041726.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EXOZ","company":"EXOZYMES INC.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"capex_increase","strength":8,"match_count":1,"context":"m the exercise of the over-allotment option will be added to working capital and other general purposes. |  Intended Use of Proceeds | |  |  | | |  | |  |  | | |  Expansion of production capabilities increase in capital expenditures | |  $ | 3,500,000 |  | | |  Increase in staff | |  $ | 5,000,000 |  | | |  Expanding Business Development, Sales, and marketing | |  $ | 500,000 |  | | |  Expanding the R&D and technology platform |","filed_date":"2024-02-09","accession":"0001493152-24-005725","full_text":"https://origin.rootz.global/static/filing/0001493152-24-005725.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"7d4e79f55e5718118a75ca42545814b9409cb54fbf4f351f740618b6eef1b6b4","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"66aeb5068e551845daceb7f091d35b3749d0a5291a3a622ca0798a0a453ca221","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":84,"hourly_limit":500,"remaining":416,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}